Viewing Study NCT02362594


Ignite Creation Date: 2025-12-25 @ 1:33 AM
Ignite Modification Date: 2026-01-03 @ 1:40 PM
Study NCT ID: NCT02362594
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-10-15
First Post: 2015-02-09
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)
Sponsor: Merck Sharp & Dohme LLC
Organization: